Business
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology
About this update from Climb Bio, Inc.
WELLESLEY, Mass. , Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024 . Poster Presentation A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous Nephropathy Presenter: Frank Cortazar , M.D., Director, New York Nephrology Vasculitis and Glomerular Center;Chief, Division of Nephrology , St. Peter's Hospital ; Chief, Clinical Research, St. Peter's Health Partners ;Clinical Scientist, Massachusetts General Hospital Session Title: Membranous Nephropathy, FSGS, and Minimal Change Disease [PO1402-1] Session Date, Time: October 24, 2024 from 10:00 a.m. to 12:00 p.m. PT Poster Board #: TH-PO587 About Climb Bio, Inc. Climb Bio, Inc. , is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com . Investors Chris Brinzey ICR Westwicke339-970-2843 Media Jon Yu ICR Westwicke [email protected] 475-395-5375 Source: Climb Bio, Inc.